Results 141 to 150 of about 65,592 (243)
Urinary microbiota diversity and composition in patients with advanced renal cell cancer
BJUI Compass, Volume 7, Issue 5, May 2026.Abstract Objectives This study aims to investigate the role of urinary microbiota in renal cell carcinoma; we analysed urinary microbiota in kidney cancer patients and explored its potential role as biomarker. Subjects and methods Samples were collected from 49 males (28 patients planned to undergo systemic therapy and 21 healthy volunteers).
Frederico Leal +7 more
wiley +1 more source
Emerging options for the treatment of melanoma – focus on ipilimumab
ImmunoTargets and Therapy, 2014 Claire Roddie, Karl S Peggs UCL Cancer Institute, Department of Hematology, London, UK Abstract: Ipilimumab is a fully human immunoglobulin subclass G1 anticytotoxic-T-lymphocyte-antigen-4 monoclonal antibody.
Roddie C, Peggs KS
doaj
Brain and Behavior, Volume 16, Issue 5, May 2026.ABSTRACT Objective Immune‐related polyradiculoneuropathy (irPRN) is a rare but potentially severe neurological adverse event secondary to immune checkpoint inhibitors (ICIs), closely resembling Guillain–Barré syndrome. This study aims to characterize the clinical presentation, neurophysiological findings, therapeutic strategies, and clinical outcomes ...
A. Llauradó +9 more
wiley +1 more source
The Immune Landscape of Acral Melanoma: From Basic to Clinical
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Background Acral melanoma (AM) is an aggressive melanoma subtype with poor prognosis and limited response to immune checkpoint inhibitors (ICIs). Despite increasing research efforts, the mechanisms underlying therapeutic resistance remain incompletely understood.
Lihong Jiang, Zhaotian Zhang
wiley +1 more source
Efficacy of Ipilimumab and Nivolumab Rechallenge in a Long-Term Melanoma Survivor: A Case Report. [PDF]
Am J Case RepVromans AM, Constantinou M.
europepmc +1 more source
Immunotherapy and Breast Reconstruction: Opportunities, Challenges, and Future Directions
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Immunotherapy is transforming breast cancer management, but it also presents new challenges for surgical and reconstructive practice. This review summarizes current evidence on immune checkpoint inhibitors, perioperative safety, and immune‐related adverse events, highlighting their impact on surgical timing, postoperative recovery, and ...
Shuang Li +6 more
wiley +1 more source
A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer). [PDF]
Future OncolYau T +27 more
europepmc +1 more source
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT The efficacy of PD‐1 inhibitor pucotenlimab (HX008) in solid tumors exhibits heterogeneity. This study integrated data from 6 clinical trials (covering gastric/gastroesophageal junction cancer, triple‐negative breast cancer, melanoma, and dMMR/MSI‐H solid tumors) using Bayesian meta‐analysis, machine learning (optimal XGBoost AUC = 0.86), and ...
Yingge He +6 more
wiley +1 more source
Past, present and future of nivolumab: new horizons in immuno-oncology. [PDF]
Front OncolMadar IH, Kammarambath SR.
europepmc +1 more source
Cancer, Volume 132, Issue 9, 1 May 2026.Abstract Background The dose escalation phase of a first‐in‐human (FIH) study demonstrated acceptable safety and preliminary antitumor activity of fianlimab (anti‐lymphocyte activation gene‐3 [LAG‐3]) as monotherapy and in combination with cemiplimab (anti‐programmed cell death‐1 [PD‐1]). Here, the authors present safety and clinical activity data from
Tae Min Kim +25 more
wiley +1 more source